Project Details


Project Narrative: Despite significant advances in the prevention and treatment of CRC in the United States (1
of the top 3 cancer types in the U.S), there remains a need for new approaches and molecular targets to
markedly reduce morbidity due to this disease. This proposal focuses on the use of a novel, selective
compound that can repress the activity of a nuclear receptor, the peroxisome proliferator-activated receptor-β/δ
(PPARβ/δ) for this purpose. The proposed studies will have high translational impact to fight this prevalent
disease using selective modulation of PPARβ/δ transcriptional activity as a mechanism to prevent/treat CRC
progression and may provide a new target for combinatorial strategies to effectively treat and/or prevent
recurrence of this disease.
Effective start/end date12/1/2011/30/22


  • National Cancer Institute: $589,136.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.